Literature DB >> 11418472

Immunodominant epitopes on glycoprotein IIb-IIIa recognized by autoreactive T cells in patients with immune thrombocytopenic purpura.

M Kuwana1, J Kaburaki, H Kitasato, M Kato, S Kawai, Y Kawakami, Y Ikeda.   

Abstract

It was recently reported that autoreactive CD4(+) T cells to glycoprotein IIb-IIIa (GPIIb-IIIa) mediate antiplatelet autoantibody production in patients with immune thrombocytopenic purpura (ITP). To further examine the antigenic specificity of the GPIIb-IIIa-reactive T cells, 6 recombinant fragments encoding different portions of GPIIbalpha or GPIIIa were generated and tested for their ability to stimulate antigen-specific T-cell proliferation and anti-GPIIb-IIIa antibody production in vitro. T cells from the peripheral blood of 25 patients with ITP and 10 healthy donors proliferated in response to recombinant GPIIb-IIIa fragments in various combinations. The amino-terminal portions of both GPIIbalpha and GPIIIa (IIbalpha18-259 and IIIa22-262) were frequently recognized (60% and 64%, respectively) compared with other fragments (4%-28%) in patients with ITP, but this tendency was not detected in healthy donors. In subsequent analyses in patients with ITP, T-cell reactivities to IIbalpha18-259 and IIIa22-262 were consistently detected, whereas those to other fragments were sometimes lost. In vitro antigenic stimulation of peripheral blood mononuclear cells with IIbalpha18-259 or IIIa22-262 promoted the synthesis of anti-GPIIb-IIIa antibodies in patients with ITP, but not in healthy donors. Of 15 CD4(+) T-cell lines specific for platelet-derived GPIIb-IIIa generated from 5 patients with ITP, 13 lines recognized IIbalpha18-259, IIIa22-262, or both. T-cell lines reactive to IIbalpha18-259 or IIIa22-262 promoted the production of anti-GPIIb-IIIa antibodies that were capable of binding to normal platelet surfaces. These results indicate that the immunodominant epitopes recognized by pathogenic CD4(+) T cells in patients with ITP are located within the amino-terminal portions of both GPIIbalpha and GPIIIa.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11418472     DOI: 10.1182/blood.v98.1.130

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  26 in total

Review 1.  Piecing together the humoral and cellular mechanisms of immune thrombocytopenia.

Authors:  Lisa J Toltl; Ishac Nazi; Reza Jafari; Donald M Arnold
Journal:  Semin Thromb Hemost       Date:  2011-11-18       Impact factor: 4.180

2.  Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura.

Authors:  Jin Yu; Susanne Heck; Vivek Patel; Jared Levan; Yu Yu; James B Bussel; Karina Yazdanbakhsh
Journal:  Blood       Date:  2008-04-17       Impact factor: 22.113

Review 3.  Pathophysiology and therapeutic options in primary immune thrombocytopenia.

Authors:  Roberto Stasi
Journal:  Blood Transfus       Date:  2010-11-26       Impact factor: 3.443

4.  Platelet-Derived Growth Factor-BB Protects Mesenchymal Stem Cells (MSCs) Derived From Immune Thrombocytopenia Patients Against Apoptosis and Senescence and Maintains MSC-Mediated Immunosuppression.

Authors:  Jia-Min Zhang; Fei-Er Feng; Qian-Ming Wang; Xiao-Lu Zhu; Hai-Xia Fu; Lan-Ping Xu; Kai-Yan Liu; Xiao-Jun Huang; Xiao-Hui Zhang
Journal:  Stem Cells Transl Med       Date:  2016-07-28       Impact factor: 6.940

5.  Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents.

Authors:  Weili Bao; James B Bussel; Susanne Heck; Wu He; Marissa Karpoff; Nayla Boulad; Karina Yazdanbakhsh
Journal:  Blood       Date:  2010-08-05       Impact factor: 22.113

6.  Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicated chronic ITP cases in Japan.

Authors:  Kingo Fujimura; Masataka Kuwana; Yoshiyuki Kurata; Masahiro Imamura; Hiroshi Harada; Hisashi Sakamaki; Masanao Teramura; Kyuhei Koda; Shosaku Nomura; Sayaka Sugihara; Takeshi Shimomura; Tetsuro-Takahiro Fujimoto; Kazuma Oyashiki; Yasuo Ikeda
Journal:  Int J Hematol       Date:  2005-02       Impact factor: 2.490

Review 7.  Helicobacter pylori infection and idiopathic thrombocytopenic purpura.

Authors:  Kingo Fujimura
Journal:  Int J Hematol       Date:  2005-02       Impact factor: 2.490

8.  Alterations in immune cell subsets and their cytokine secretion profile in childhood idiopathic thrombocytopenic purpura (ITP).

Authors:  R M Talaat; A M Elmaghraby; S S Barakat; M El-Shahat
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

9.  T cell receptor VB repertoire diversity in patients with immune thrombocytopenia following splenectomy.

Authors:  P F Fogarty; M E Rick; W Zeng; A M Risitano; C E Dunbar; J B Bussel
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

10.  Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura.

Authors:  Ellinor I B Peerschke; Biree Andemariam; Wei Yin; James B Bussel
Journal:  Br J Haematol       Date:  2009-11-19       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.